Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Accounts Payables (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Accounts Payables for 10 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 61.54% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, down 61.54%, and an annual FY2025 reading of $1.0 million, down 61.54% over the prior year.
  • Accounts Payables was $1.0 million for Q4 2025 at VYNE Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $10.1 million in Q2 2021 and bottomed at $716000.0 in Q3 2023.
  • Average Accounts Payables over 5 years is $3.3 million, with a median of $2.7 million recorded in 2024.
  • The sharpest move saw Accounts Payables crashed 85.8% in 2022, then soared 456.7% in 2024.
  • Year by year, Accounts Payables stood at $6.5 million in 2021, then plummeted by 63.35% to $2.4 million in 2022, then tumbled by 30.47% to $1.7 million in 2023, then soared by 63.17% to $2.7 million in 2024, then tumbled by 61.54% to $1.0 million in 2025.
  • Business Quant data shows Accounts Payables for VYNE at $1.0 million in Q4 2025, $1.4 million in Q2 2025, and $3.5 million in Q1 2025.